NYSE:AORT Artivion (AORT) Stock Price, News & Analysis $23.73 -0.11 (-0.46%) Closing price 04/28/2025 03:59 PM EasternExtended Trading$23.72 -0.01 (-0.04%) As of 04/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Artivion Stock (NYSE:AORT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Artivion alerts:Sign Up Key Stats Today's Range$23.46▼$24.0550-Day Range$22.13▼$28.9152-Week Range$19.36▼$32.33Volume276,719 shsAverage Volume299,471 shsMarket Capitalization$1.01 billionP/E RatioN/ADividend YieldN/APrice Target$31.40Consensus RatingBuy Company OverviewArtivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Read More… Artivion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreAORT MarketRank™: Artivion scored higher than 64% of companies evaluated by MarketBeat, and ranked 642nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArtivion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArtivion has only been the subject of 2 research reports in the past 90 days.Read more about Artivion's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth35.14% Earnings GrowthEarnings for Artivion are expected to grow by 35.14% in the coming year, from $0.37 to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artivion is -1,186.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artivion is -1,186.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtivion has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Artivion's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.87% of the float of Artivion has been sold short.Short Interest Ratio / Days to CoverArtivion has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Artivion has recently decreased by 5.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtivion does not currently pay a dividend.Dividend GrowthArtivion does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.87% of the float of Artivion has been sold short.Short Interest Ratio / Days to CoverArtivion has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Artivion has recently decreased by 5.11%, indicating that investor sentiment is improving significantly. News and Social Media1.6 / 5News Sentiment0.81 News SentimentArtivion has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Artivion this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Artivion to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,356,223.00 in company stock.Percentage Held by InsidersOnly 8.10% of the stock of Artivion is held by insiders.Percentage Held by Institutions86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Artivion's insider trading history. Receive AORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter. Email Address AORT Stock News HeadlinesReviewing Artivion (NYSE:AORT) and Penumbra (NYSE:PEN)April 23, 2025 | americanbankingnews.comArtivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial ResultsApril 21, 2025 | prnewswire.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 29, 2025 | American Alternative (Ad)Unpacking Q4 Earnings: Artivion (NYSE:AORT) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular StocksApril 15, 2025 | finance.yahoo.comInvestors in Artivion (NYSE:AORT) have seen returns of 15% over the past yearApril 14, 2025 | finance.yahoo.comArtivion (AORT): Buy, Sell, or Hold Post Q4 Earnings?March 28, 2025 | msn.comDo Options Traders Know Something About Artivion (AORT) Stock We Don't?March 24, 2025 | finance.yahoo.comArtivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services ConferenceMarch 4, 2025 | prnewswire.comSee More Headlines AORT Stock Analysis - Frequently Asked Questions How have AORT shares performed this year? Artivion's stock was trading at $28.59 at the start of the year. Since then, AORT shares have decreased by 17.0% and is now trading at $23.73. View the best growth stocks for 2025 here. How were Artivion's earnings last quarter? Artivion, Inc. (NYSE:AORT) announced its quarterly earnings results on Monday, February, 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by $0.51. The business had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. Artivion had a negative net margin of 0.22% and a positive trailing twelve-month return on equity of 5.15%. Read the conference call transcript. Who are Artivion's major shareholders? Artivion's top institutional investors include Peregrine Capital Management LLC (0.73%), Principal Financial Group Inc. (0.48%), Rhumbline Advisers (0.26%) and New York State Teachers Retirement System (0.14%). Insiders that own company stock include James P Mackin, David Ashley Lee, John E Davis, Jean F Holloway, Amy Horton, Marshall S Stanton, Lance A Berry, Rochelle L Maney, Dennis B Maier, Anthony B Semedo, Matthew A Getz and Andrew M Green. View institutional ownership trends. How do I buy shares of Artivion? Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artivion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artivion investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings2/24/2025Today4/29/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:AORT CIK784199 Webwww.cryolife.com Phone(770) 419-3355Fax770-426-0031Employees1,300Year FoundedN/APrice Target and Rating Average Stock Price Target$31.40 High Stock Price Target$33.00 Low Stock Price Target$30.00 Potential Upside/Downside+32.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E Ratio64.14 P/E GrowthN/ANet Income$-30,690,000.00 Net Margins-0.22% Pretax Margin2.21% Return on Equity5.15% Return on Assets1.91% Debt Debt-to-Equity Ratio0.71 Current Ratio1.88 Quick Ratio1.33 Sales & Book Value Annual Sales$388.54 million Price / Sales2.61 Cash Flow$0.65 per share Price / Cash Flow36.78 Book Value$6.87 per share Price / Book3.45Miscellaneous Outstanding Shares42,689,000Free Float38,524,000Market Cap$1.01 billion OptionableOptionable Beta1.65 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:AORT) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artivion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.